Semaglutide vs Retatrutide: GLP-1 vs Triple Agonist Comparison
Semaglutide is an FDA-approved selective GLP-1 receptor agonist (Ozempic/Wegovy) with extensive clinical data showing ~15-17% body weight loss. Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, with Phase 2 data showing up to 24.2% weight loss at 48 weeks -- potentially the most effective weight loss compound ever studied. This comparison examines the established standard of care versus the next-generation triple-agonist approach.
Side-by-Side Comparison
| Parameter | Semaglutide | Retatrutide |
|---|---|---|
| Mechanism | Selective GLP-1 receptor agonist | Triple agonist: GLP-1 + GIP + Glucagon receptors |
| Evidence Grade | A+ | B |
| Route | Subcutaneous (weekly) | Subcutaneous (weekly) |
| Dose Range | 0.25 - 2.4 mg/week | 0.5 - 12 mg/week (Phase 2) |
| Half-Life | ~7 days | ~6 days |
| Weight Loss (trials) | ~14.9 - 16.9% (STEP trials, 68 wk) | ~22 - 24.2% (Phase 2, 48 wk) |
| Unique Feature | Proven CV benefit (SELECT trial) | Glucagon receptor agonism increases energy expenditure |
| Liver Fat Reduction | Moderate (NASH data emerging) | Dramatic (~86% reduction in Phase 2 MASLD sub-study) |
| FDA Status | Approved (T2D 2017, obesity 2021) | Not approved; Phase 3 trials (TRIUMPH) |
| Developer | Novo Nordisk | Eli Lilly |
| Clinical Data Depth | Extensive (1000+ publications, large RCTs) | Early (Phase 2 published, Phase 3 ongoing) |
| GI Side Effects | Common (nausea, vomiting during titration) | Common (similar GI profile to semaglutide) |
| Cost (research grade) | $$ | $$$ (limited availability) |
Semaglutide: Pros & Cons
Advantages
- FDA-approved with extensive real-world safety data
- Proven 20% cardiovascular risk reduction (SELECT trial)
- Oral formulation available (Rybelsus)
- Largest evidence base of any incretin therapy
- Well-characterized side effect profile
- Widely available and increasingly covered by insurance
Considerations
- Lower peak weight loss vs retatrutide in cross-trial comparisons
- GI side effects common during titration
- Weight regain after discontinuation
- Single-receptor mechanism limits metabolic scope
- Limited direct liver fat reduction data
Retatrutide: Pros & Cons
Advantages
- Highest recorded weight loss in clinical trials (24.2%)
- Triple mechanism targets multiple metabolic pathways
- Glucagon component increases energy expenditure
- Dramatic liver fat reduction (~86% in MASLD sub-study)
- Potentially addresses metabolic syndrome more comprehensively
- May reduce weight regain due to metabolic rate effects
Considerations
- Not FDA-approved; still in Phase 3 trials
- Very limited long-term safety data
- No cardiovascular outcomes data yet
- Glucagon agonism may raise blood sugar (theoretical)
- Limited availability at research grade
- Higher cost and less supplier competition
Which Is Right for Your Research?
Decision Guide
Choose Semaglutide if: You need a well-characterized compound with FDA approval, extensive safety data, proven cardiovascular benefit, and the deepest clinical evidence base of any incretin. Semaglutide is the established standard in GLP-1 research with an A+ evidence grade and real-world data from millions of patients.
Choose Retatrutide if: You are investigating the frontier of multi-agonist metabolic pharmacology, maximal weight loss efficacy, or liver fat reduction. Retatrutide's triple mechanism represents the most advanced approach to incretin-based metabolic intervention, with Phase 2 data showing unprecedented weight loss. Its glucagon component adds a unique energy expenditure dimension not found in GLP-1-only compounds.
Important context: Semaglutide is an A+-graded, FDA-approved compound with proven outcomes. Retatrutide is a B-graded investigational compound with extraordinary Phase 2 results but limited long-term data. For established research, semaglutide is the safer evidence-based choice. For exploratory research on next-generation metabolic therapies, retatrutide represents the cutting edge.
Frequently Asked Questions
Early clinical data suggests retatrutide may produce greater weight loss. Phase 2 data showed 24.2% body weight loss at 48 weeks with retatrutide 12mg, compared to ~16.9% with semaglutide 2.4mg at 68 weeks. However, these are cross-trial comparisons and Phase 3 results are needed for definitive conclusions.
Retatrutide activates three receptors simultaneously (GLP-1, GIP, and glucagon) while semaglutide only activates GLP-1. The glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation, potentially contributing to greater weight loss and liver fat reduction beyond what GLP-1 alone achieves.
Retatrutide is currently in Phase 3 clinical trials (TRIUMPH program) by Eli Lilly. If trials are successful, FDA submission could occur in 2026-2027 with potential approval in 2027-2028. Timelines are subject to change based on trial outcomes. Semaglutide remains the established option with current FDA approval.
Related Protocol Guides
Verified Research Suppliers
Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards.
Related Tools & Resources
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.